MARKSANS PHARMA
|
The Current P/E Ratio of MARKSANS PHARMA is 29.14.
| Share Price | ₹335.2 | Sep 07,2026 |
| Market Cap | ₹15,189.0 Cr | |
| Earnings-TTM | ₹521.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 29.14x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MARKSANS PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹15,189.0 Cr] as on Sep 07,2026
(/) Earnings [ ₹521.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 29.14x ]
Thus, for MARKSANS PHARMA , the investors are currently willing to pay 29.14 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MARKSANS PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MARKSANS PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MARKSANS PHARMA
PE Ratio Performance Analysis for MARKSANS PHARMA
- MARKSANS PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 17.50x.
- MARKSANS PHARMA 's operated at median p/e ratio of 17.04x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MARKSANS PHARMA 's p/e ratio peaked in Mar2025 at 26.48x.
- MARKSANS PHARMA 's p/e ratio hit its five-year low in Mar2022 of 10.1x.
How does MARKSANS PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MARKSANS PHARMA | 521.27 | 29.14 | 15,189.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.45 | 455,826.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.45 | 247,019.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 86.68 | 186,875.0 |
| CIPLA LTD | 3,364.84 | 33.52 | 112,773.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.16 | 95,570.9 |
| MANKIND PHARMA LTD | 2,055.11 | 46.67 | 95,911.1 |
| LUPIN LTD | 5,551.01 | 17.34 | 96,254.5 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.65 | 115,212.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.69 | 95,397.6 |
| LAURUS LABS LTD | 1,090.76 | 92.54 | 100,944.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MARKSANS PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.34x |
| Max industry PE | 92.54x |
| Median industry PE | 33.52x |
| Average industry PE | 46.30x |
You may also like the below Video Courses